Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G<sub>1</sub> cell cycle arrest

Kambara,Takahiro; Amatya,Vishwa Jeet; Kushitani,Kei; Fujii,Yutaro; Endo,Ihiro; Takeshima,Yukio

doi:10.3892/ol.2022.13294

Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G₁ cell cycle arrest

Authors:
- Takahiro Kambara
- Vishwa Jeet Amatya
- Kei Kushitani
- Yutaro Fujii
- Ihiro Endo
- Yukio Takeshima
View Affiliations

Affiliations: Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734‑8551, Japan
Published online on: April 13, 2022 https://doi.org/10.3892/ol.2022.13294
Article Number: 174
Copyright: © Kambara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pleural malignant mesothelioma is a malignant tumor with a poor prognosis that is strongly associated with asbestos exposure during its development. Because there is no adequate treatment for malignant mesothelioma, investigation of its molecular mechanism is important. The ferritin light chain (FTL) is a subunit of ferritin, and its high expression in malignant tumors, including malignant mesothelioma, has recently been reported; however, its role in malignant mesothelioma is unclear. The purpose of the present study was to clarify the function of FTL in malignant mesothelioma. The expression levels of FTL in malignant mesothelioma were examined using the Cancer Cell Line Encyclopedia database and our previous data. The short interfering (si)RNA against FTL was transfected into two mesothelioma cell lines, ACC‑MESO‑1 and CRL‑5915, and functional analysis was performed. Expression of p21, p27, cyclin‑dependent kinase 2 (CDK2) and phosphorylated retinoblastoma protein (pRb) associated with the cell cycle were examined as candidate genes associated with FTL. The expression levels of the FTL mRNA were higher in malignant mesothelioma compared with other tumors in the Cancer Cell Line Encyclopedia database, and among other genes in our previous study. Reverse transcription‑quantitative PCR and western blotting demonstrated suppression of FTL expression in two cell lines transfected with FTL siRNA compared with cells transfected with negative control (NC) siRNA. In the two cell lines transfected with FTL siRNA, proliferation was significantly suppressed, and cell cycle arrest was observed in the G₁ phase. The levels of p21 and p27 were increased, while those of CDK2 and pRb were decreased compared with NC. However, no significant differences in invasion and migration ability were revealed between FTL siRNA‑transfected cells and NC. In conclusion, FTL may increase the proliferative capacity of malignant mesothelioma cells by affecting p21, p27, CDK2 and pRb, and promoting the cell cycle at the G₁ phase.

View Figures

View References

1	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
2	Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 89:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
3	Alkhateeb AA and Connor JR: The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 1836:245–254. 2013.PubMed/NCBI
4	Gomez DR, Rimner A, Simone CB II, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, et al: The use of radiation therapy for the treatment of malignant pleural mesothelioma: Expert opinion from the National Cancer Institute thoracic malignancy steering committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 14:1172–1183. 2019. View Article : Google Scholar : PubMed/NCBI
5	de Gooijer CJ, Baas P and Burgers JA: Current chemotherapy strategies in malignant pleural mesothelioma. Transl Lung Cancer Res. 7:574–583. 2018. View Article : Google Scholar : PubMed/NCBI
6	Aung W, Hasegawa S, Furukawa T and Saga T: Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: Implications for asbestos-induced oncogenesis. Carcinogenesis. 28:2047–2052. 2007. View Article : Google Scholar : PubMed/NCBI
7	Li Z, Liu J, Chen H, Zhang Y, Shi H, Huang L, Tao J, Shen R and Wang T: Ferritin light chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. Carcinogenesis. 41:467–477. 2020. View Article : Google Scholar : PubMed/NCBI
8	Zhang L, Chen Z and Xu A: FTL: A novel predictor in gastric cancer. Int J Clin Exp Pathol. 10:7865–7872. 2017.PubMed/NCBI
9	Wu T, Li Y, Liu B, Zhang S, Wu L, Zhu X and Chen Q: Expression of ferritin light chain (FTL) is elevated in glioblastoma, and FTL silencing inhibits glioblastoma cell proliferation via the GADD45/JNK pathway. PLoS One. 11:e01493612016. View Article : Google Scholar : PubMed/NCBI
10	Huang H, Qiu Y, Huang G, Zhou X, Zhou X and Luo W: Value of Ferritin Heavy Chain (FTH1) Expression in diagnosis and prognosis of renal cell carcinoma. Med Sci Monit. 19:3700–3715. 2019. View Article : Google Scholar : PubMed/NCBI
11	Mohr S, Bottin MC, Lannes B, Neuville A, Bellocq JP, Keith G and Rihn BH: Microdissection, mRNA amplification and microarray: A study of pleural mesothelial and malignant mesothelioma cells. Biochimie. 86:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
12	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T and Takeshima Y: Identification of DAB2 and Intelectin-1 as novel positive immunohistochemical markers of epithelioid mesothelioma by transcriptome microarray analysis for its differentiation from pulmonary adenocarcinoma. Am J Surg Pathol. 41:1045–1052. 2017. View Article : Google Scholar : PubMed/NCBI
14	Lamprecht MR, Sabatini DM and Carpenter AE: CellProfiler: Free, versatile software for automated biological image analysis. Biotechniques. 42:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cao C, Tian D, Park J, Allan J, Pataky KA and Yan TD: A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 83:240–245. 2014. View Article : Google Scholar : PubMed/NCBI
16	Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M and Pass HI: Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 5:1649–1654. 2010. View Article : Google Scholar : PubMed/NCBI
17	Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI
18	Li Z, Jiang L, Chew SH, Hirayama T, Sekido Y and Toyokuni S: Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia. Redox Biol. 26:1012972019. View Article : Google Scholar : PubMed/NCBI
19	Shi L, Ito F, Wang Y, Okazaki Y, Tanaka H, Mizuno M, Hori M, Hirayama T, Nagasawa H, Richardson DR and Toyokuni S: Non-thermal plasma induces a stress response in mesothelioma cells resulting in increased endocytosis, lysosome biogenesis and autophagy. Free Radic Biol Med. 108:904–917. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT and Harper JW: Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 14:2298–2313. 2000. View Article : Google Scholar : PubMed/NCBI
21	Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE and Fukasawa K: Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 103:127–140. 2000. View Article : Google Scholar : PubMed/NCBI
22	Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE and Knudsen ES: Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol Cell Biol. 21:4032–4045. 2001. View Article : Google Scholar : PubMed/NCBI
23	Herrera RE, Sah VP, Williams BO, Mäkelä TP, Weinberg RA and Jacks T: Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol. 16:2402–2407. 1996. View Article : Google Scholar : PubMed/NCBI
24	Zhu W, Giangrande PH and Nevins JR: E2Fs link the control of G1/S and G2/M transcription. EMBO J. 23:4615–4626. 2004. View Article : Google Scholar : PubMed/NCBI
25	Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ and Knudsen ES: Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res. 62:6587–6597. 2002.PubMed/NCBI
26	Möröy T and Geisen C: Cyclin E. Int J Biochem Cell Biol. 36:1424–1439. 2004. View Article : Google Scholar : PubMed/NCBI
27	Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI
28	Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, et al: Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA. 108:3761–3766. 2011. View Article : Google Scholar : PubMed/NCBI
29	Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massagué J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:59–66. 1994. View Article : Google Scholar : PubMed/NCBI
30	van den Heuvel S and Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 262:2050–2054. 1993. View Article : Google Scholar : PubMed/NCBI